Anika reports inducement grants
Anika Therapeutics, Inc. announced that it granted restricted stock units (RSUs) covering 3,360 shares of common stock to a newly hired non-executive employee on June 1, 2026. This grant was made under the company's 2021 Inducement Plan and was approved by the compensation committee as a material inducement for the employee's acceptance of employment. The RSUs will vest in three equal installments over three years, contingent on continuous service.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics, Inc. announced inducement grants of restricted stock units (RSUs) covering 3,360 shares of common stock to a newly hired non-executive employee on June 1, 2026. This grant was made under the Anika Therapeutics, Inc. 2021 Inducement Plan and was approved by the compensation committee, serving as a material inducement for the employee's acceptance of employment. The RSUs will vest in three equal installments over three years, contingent on continuous service.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics, Inc. announced the grant of restricted stock units (RSUs) covering 3,360 shares of common stock to a new non-executive employee on June 1, 2026. This grant, made under the Anika Therapeutics, Inc. 2021 Inducement Plan, serves as a material inducement for the employee's acceptance of employment and will vest in three equal annual installments.
Anika Therapeutics grants 3,360 RSUs to new employee as inducement under Nasdaq rules.
Anika Therapeutics has granted 3,360 restricted stock units (RSUs) to a new non-executive employee. This grant, made on June 1, 2026, serves as an inducement for employment under Nasdaq rules and will vest in equal installments over three years, dependent on continuous service. The move is part of Anika's strategy to attract skilled talent for its osteoarthritis pain management and regenerative solutions business.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics, Inc. announced the grant of 3,360 restricted stock units (RSUs) to a new non-executive employee on June 1, 2026. This grant was an inducement for employment, pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in three equal annual installments, contingent on continuous service.
New Anika hire receives 3,360 stock units as job inducement
Anika Therapeutics (NASDAQ: ANIK) announced it granted 3,360 restricted stock units (RSUs) to a newly hired non-executive employee as a material inducement for employment. The grant, effective June 1, 2026, was made under the 2021 Inducement Plan and Nasdaq Listing Rule 5635(c)(4), vesting in three equal annual installments over three years contingent on continuous service. This compensation event is considered routine, with similar prior grants having minimal stock price impact.
Anika (NASDAQ: ANIK) CEO exercises RSUs, withholds shares to cover tax
Anika Therapeutics President and CEO, Stephen D. Griffin, exercised 12,840 restricted stock units (RSUs) on June 3, 2026, which converted into common shares. The company withheld 3,769 shares to cover tax obligations related to this vesting event. Following these transactions, Mr. Griffin directly holds 49,742 shares of Anika common stock, marking the second of three equal annual installments from a 2024 RSU grant.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics, Inc. announced the grant of restricted stock units (RSUs) covering 3,360 shares to a newly hired non-executive employee on June 1, 2026. This grant was made as a material inducement for employment under the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, and in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in three equal installments on the first three anniversaries of the grant date, contingent on continuous service.
Trading Systems Reacting to (ANIK) Volatility
Quantitative Research Desk reports on Anika Therapeutics Inc. (NASDAQ: ANIK) volatility, noting a near-term neutral sentiment amidst mid and long-term strength. The article details institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for the stock. Key findings include a mid-channel oscillation pattern and an exceptional risk-reward profile for a short setup.
Anika Therapeutics invites ESSKA Congress delegates to explore advances in HA-based cartilage repair
Anika Therapeutics is scheduled to participate in the upcoming ESSKA Congress to discuss advancements in cartilage restoration and tendon repair, focusing on their HA-based technology. The company aims to engage with specialists to demonstrate how these innovations are applied in orthopedic settings. This follows their recent launch of the Integrity Implant System at the Shoulder360 conference, where they also offered demo requests for the product.
About Us | Oil & Gas Journal - Anika Therapeutics Inc. - Common Stock (Nasdaq:ANIK) Stock Quote
This page provides a detailed stock quote for Anika Therapeutics Inc. (Nasdaq: ANIK), including its current price, market performance, trading volume, and key financial metrics. It also features a timeline of recent news and earnings reports related to the company, highlighting announcements and investigations, and offers answers to frequently asked questions about its stock. The content is presented by the Oil & Gas Journal, serving as a platform for financial data.
Anika maintains 2026 revenue guidance of $114M-$122.5M while highlighting Integrity growth and Hyalofast FDA response work
Anika Therapeutics reaffirmed its 2026 revenue guidance, projecting between $114 million and $122.5 million. The company emphasized the growth of its Integrity product line and its ongoing efforts in preparing a response to the FDA regarding Hyalofast. This guidance underscores Anika's confidence in its strategic initiatives and product pipeline.
How Anika Therapeutics Inc. (ANIK) Affects Rotational Strategy Timing
Anika Therapeutics Inc. (ANIK) is exhibiting a mix of positive near-term sentiment within a long-term strong context, despite a mid-term weak bias. AI models have generated three trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with specific entry, target, and stop-loss levels. The analysis highlights an exceptional 63.2:1 risk-reward short setup, signaling potential downside.
Anika Therapeutics explores why skin heals rapidly but tendons and cartilage lag in recovery
Anika Therapeutics is investigating the significant difference in healing rates between skin and musculoskeletal tissues like tendons and cartilage. While skin heals quickly, these deeper tissues take much longer, affecting long-term joint recovery and mobility. The company attributes this disparity to fundamental biological differences and is actively researching innovative approaches to accelerate tissue regeneration for improved patient outcomes.
Number of shareholders of Anika Therapeutics Inc. – NASDAQ:ANIK
This article from TradingView provides information on the number of shareholders for Anika Therapeutics Inc. (NASDAQ: ANIK). The content appears to be a stub or a placeholder, as it doesn't contain the actual shareholder numbers but rather describes the navigation path to find financial data on the company. It serves as a gateway to financial information provided by ICE Data Services and FactSet.
Anika maintains 2026 revenue guidance of $114M-$122.5M while highlighting Integrity growth and Hyalofast FDA response work
Anika Therapeutics (ANIK) has reaffirmed its 2026 revenue guidance of $114 million to $122.5 million. The company is focusing on the growth of its Integrity product line and its ongoing efforts to prepare a response to the FDA regarding Hyalofast. This guidance indicates the company's continued strategic direction despite recent market conditions.
Anika Therapeutics director John Henneman buys $73,319 in shares
Anika Therapeutics director John B. Henneman, III, recently purchased 5,000 shares of the company's common stock for $73,319, with shares bought at a weighted average price of $14.6639. This transaction follows a 54% surge in ANIK shares over the past six months. Despite the stock appearing overvalued according to InvestingPro, Anika Therapeutics reported strong Q1 2026 results, beating EPS and revenue forecasts.
Anika Therapeutics director John Henneman buys $73,319 in shares
Anika Therapeutics director John Henneman recently purchased 5,000 shares of the company's common stock worth $73,319, following a 54% surge in ANIK shares over the past six months. This transaction increases his direct holdings to 54,871 shares. The purchase follows Anika Therapeutics' strong Q1 2026 financial results, which significantly beat EPS and revenue forecasts.
Anika Therapeutics (ANIK) director adds 5,000 shares in open-market buy
John B. Henneman III, a director at Anika Therapeutics (ANIK), recently purchased 5,000 shares of the company's common stock in an open-market transaction. The shares were acquired at a weighted average price of $14.6639 per share, totaling approximately $73,320. Following this purchase, Mr. Henneman now directly holds 54,871 shares of Anika Therapeutics.
President of Anika Therapeutics Picks Up 51% More Stock
The President of Anika Therapeutics (NASDAQ:ANIK), Stephen Griffin, recently purchased US$150k worth of company stock at US$12.29 per share, increasing his holding by 51%. This move signals optimism from the insider, even though the purchase price was significantly below the current market price of US$14.85. While insider ownership is noted at 4.7%, a lack of company profit in the last year warrants caution despite the positive signal from insider buying.
Anika Therapeutics (NASDAQ:ANIK) Rating Lowered to "Buy" at Wall Street Zen
Wall Street Zen downgraded Anika Therapeutics (NASDAQ:ANIK) from a "strong-buy" to a "buy" rating, although Barrington Research raised its price target to $17, maintaining a consensus "Hold" rating with a $17 target. Despite beating earnings estimates with $0.27 EPS, the biotechnology company still faces weak outlooks, including a negative net margin and a forecast of -0.61 EPS for the fiscal year. Insider confidence was demonstrated by CEO Stephen Griffin, who increased his holdings by over 50% by purchasing 12,200 shares.
Anika Therapeutics (NASDAQ:ANIK) CEO Purchases $149,938.00 in Stock
Anika Therapeutics (NASDAQ:ANIK) CEO Stephen Griffin purchased 12,200 shares of the company's stock for $149,938.00 on April 30th, increasing his stake by over 50%. This insider buying occurred after the company reported better-than-expected Q1 earnings, with EPS of $0.27 against an estimated -$0.07, and revenue of $29.6M. Despite the positive earnings beat and increased gross margin, the company remains unprofitable on a trailing basis, and analysts still project negative full-year EPS.
Anika Therapeutics’ CEO Stephen Griffin buys $149,880 in company stock
Anika Therapeutics' CEO, Stephen Griffin, acquired 12,200 shares of the company's common stock for $149,880 after a recent stock drop. This purchase increased his direct holdings to 36,163 shares and occurred despite the company reporting strong Q1 2026 financial results that exceeded expectations. The context suggests a CEO's confidence in the company following a market dip.
Anika Therapeutics (ANIK) CEO buys 12,200 shares in open market
Anika Therapeutics' President and CEO, Stephen D. Griffin, purchased 12,200 shares of the company's common stock on April 30, 2026, at a weighted average price of $12.2853 per share, totaling approximately $150,000. Following this open-market transaction, Griffin directly holds 36,163 shares of ANIK. This insider buying signals positive sentiment from the company's leadership regarding its prospects.
Anika Therapeutics Q1 2026 earnings preview
This article provides a preview of Anika Therapeutics' upcoming Q1 2026 earnings report. It indicates that further details about the earnings are expected.
Insider Buying: Stephen Griffin Acquires Shares of Anika Therapeutics Inc (ANIK)
Stephen Griffin, President and CEO of Anika Therapeutics Inc (ANIK), recently purchased 12,200 shares, increasing his total holdings to 36,163 shares. This transaction suggests positive insider sentiment, as it is the only insider buy in the past year with no sells. The stock is currently trading at $12.29, which is significantly undervalued compared to its GF Value of $21.90, indicating potential for investors.
Anika Therapeutics’ CEO Stephen Griffin buys $149,880 in company stock
Anika Therapeutics' CEO, Stephen Griffin, purchased 12,200 shares of company stock for $149,880 on April 30, 2026, after the stock experienced a nearly 20% decline. This purchase increased his direct holdings to 36,163 shares. Despite the stock's apparent overvaluation according to InvestingPro, analysts maintain optimistic price targets of $17-18, and the company recently reported strong Q1 2026 financial results, surpassing revenue and EPS expectations.
Anika Therapeutics : 2026 Proxy Statement
Anika Therapeutics, Inc. has released its 2026 Proxy Statement, detailing the agenda for its upcoming Annual Meeting of Stockholders on June 18, 2026. Key proposals include the election of three Class III Directors, ratification of Deloitte & Touche LLP as independent auditor, an advisory vote on 2025 executive compensation, and amendments to the 2017 Omnibus Incentive Plan and 2021 Employee Stock Purchase Plan to increase authorized shares. The company highlighted strong 2025 performance, driven by its OA Pain Management and Regenerative Solutions businesses, and reiterated its strategy for long-term growth focused on commercial channel acceleration, pipeline advancement, and operational discipline.
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2026 Earnings Call Transcript
Anika Therapeutics (NASDAQ: ANIK) reported strong first-quarter 2026 results, exceeding earnings expectations with an EPS of $0.27 against a $-0.07 forecast. The company highlighted significant progress in driving commercial channel growth, advancing its HA-based innovation pipeline, and strengthening operational execution, leading to a 13% year-over-year revenue increase and improved gross margins. Anika maintained its full-year 2026 financial guidance, anticipating continued growth in its commercial channels and focused investments in key pipeline programs like Integrity, Hyalofast, and CINGAL.
Revenue climbs 13% as Anika Therapeutics (NASDAQ: ANIK) boosts margins but stays in loss
Anika Therapeutics, Inc. reported a 13% increase in Q1 2026 revenue to $29.6 million, driven by strong OEM and international OA pain and regenerative product sales. Despite an improved gross margin of 64%, the company posted a net loss of $5.1 million, primarily due to higher stock-based compensation and restructuring costs including severance related to a CEO transition. Anika's adjusted EBITDA turned positive at $4.3 million, and it maintains a strong cash position with $41.0 million in cash and no debt, while continuing its share repurchase program.
Anika Therapeutics (ANIK) Q4 Profit Challenges Ongoing Unprofitability Narrative Ahead Of Q1 Earnings
Anika Therapeutics (ANIK) reported Q4 2025 revenue of US$30.6 million and basic EPS of US$0.13, showing a shift towards profitability from previous losses. Despite this positive quarterly performance, the company's trailing twelve-month revenue was US$112.8 million with a net loss of US$10.0 million and basic EPS of -US$0.70. Analysts predict Anika will remain unprofitable for the next three years, though its current P/S ratio and valuation suggest potential upside if it achieves promised profit margins.
Vanguard (ANIK) discloses 695,697 shares, a 5.19% stake (Schedule 13G)
Vanguard Capital Management has filed a Schedule 13G, disclosing a 5.19% passive stake in Anika Therapeutics Inc (ANIK), amounting to 695,697 shares. The filing indicates Vanguard has sole voting power over 89,920 shares and sole dispositive power over all 695,697 shares, aggregated across Vanguard entities. This disclosure is a regulatory requirement for significant passive investments and does not suggest activist intent.
[ARS] Anika Therapeutics, Inc. SEC Filing
This article announces an SEC filing (Form ARS) for Anika Therapeutics, Inc. (ANIK) from April 28, 2026. The filing is categorized as having a low impact and neutral sentiment. The article also provides a link to view the full PDF document on SEC EDGAR and offers an overview of ANIK's stock information, recent news, and other SEC filings.
Anika Therapeutics Releases Q1 2026 Financial Results
Anika Therapeutics (ANIK) reported strong Q1 2026 financial results, with adjusted earnings of $0.27 per share significantly beating consensus estimates of a $0.16 loss per share. The company's revenue increased by 13.0% to $29.6 million, driven by its OEM Channel, and management provided full-year revenue guidance of $114.0M to $122.5M. The results indicate a notable turnaround for the orthopedics specialist, with Wall Street maintaining a constructive outlook on the stock.
Anika Therapeutics Posts Strong Q1 2026 Revenue Growth
Anika Therapeutics reported a robust Q1 2026 with revenue up 13% to $29.6 million and adjusted EBITDA climbing to $4.3 million, driven by strong growth in Commercial and OEM channels and improved gross margins. The company reaffirmed its full-year 2026 guidance for top-line growth and adjusted EBITDA margins between 5% and 10, completing a $15 million share repurchase and preparing for a board restructure. Analysts currently rate ANIK stock as a Buy with a $17.00 price target, while TipRanks' AI Analyst, Spark, rates it Neutral.
Anika Therapeutics Q1 2026 earnings preview
This article provides a preview of Anika Therapeutics' first quarter 2026 earnings. It is a placeholder indicating that a more detailed earnings report will follow.
Anika Therapeutics Q1 2026 earnings preview
This article provides a preview of Anika Therapeutics' upcoming Q1 2026 earnings report. It does not contain any further information or details regarding the expected results or analysis.
Anika Therapeutics Q1 Earnings Call Highlights
Anika Therapeutics reported strong Q1 2026 results, with total revenue up 13% to $29.6 million, driven by double-digit commercial channel growth, particularly from its Integrity product and international OA sales. The company achieved significant margin expansion, with GAAP gross margin increasing to 64%, and reiterated its full-year 2026 revenue guidance of $114-$122.5 million. Anika also provided updates on its pipeline, including ongoing Hyalofast PMA review, progress in Cingal's bioequivalence study, and encouraging preclinical data for an early-stage suture/tape program.
Is Anika Therapeutics (ANIK) 30.3% Undervalued After Q1 2026 Earnings?
Anika Therapeutics (ANIK) reported Q1 2026 earnings, beating revenue estimates ($29.6M vs $28.14M est) but missing EPS expectations (-$0.37 vs -$0.16 est). The company saw 13% revenue growth, improved gross margin to 64.2%, and better adjusted EBITDA. GuruFocus assesses ANIK as 30.3% undervalued based on its GF Value, despite GAAP losses due to one-time severance costs and increased operating expenses.
Anika Therapeutics Releases Q1 2026 Financial Results
Anika Therapeutics (ANIK) reported strong Q1 2026 financial results, with adjusted earnings of $0.27 per share significantly surpassing the consensus estimate loss of $0.16. The company also posted a 13.0% increase in revenue to $29.6 million, largely driven by its OEM Channel. Management provided full-year revenue guidance between $114.0 million and $122.5 million, and Wall Street maintains a positive outlook on the stock with mostly buy ratings.
ANIKA THERAPEUTICS ($ANIK) Releases Q1 2026 Earnings
ANIKA THERAPEUTICS ($ANIK) announced its Q1 2026 earnings, reporting $0.27 per share, significantly surpassing estimates of -$0.16. The company also exceeded revenue expectations, bringing in $29,610,000 against an estimated $28,704,840. This positive earnings report follows recent hedge fund activity showing increased institutional investment in ANIK, and a recent "Outperform" rating from Barrington Research.
Anika: Q1 Earnings Snapshot
Anika Therapeutics Inc. (ANIK) reported a first-quarter loss of $5.1 million, or 37 cents per share, adjusted to 27 cents per share. The medical technology company posted $29.6 million in revenue and anticipates full-year revenue between $114 million and $122.5 million. The company's shares have seen a 59% increase year-to-date and a 5% rise over the last 12 months.
Anika Reports First Quarter 2026 Financial Results
Anika Therapeutics Inc. reported strong first-quarter 2026 financial results, with total revenue increasing 13% to $29.6 million, driven by growth in both its Commercial and OEM channels. The company achieved a 64% gross margin, an 8-point improvement year-over-year, and generated $4.3 million in adjusted EBITDA. These results reflect the success of Anika's strategic transformation and operational improvements, leading to increased profitability and efficiency.
Double-digit Q1 growth at Anika (NASDAQ: ANIK) as margins rise
Anika Therapeutics reported strong Q1 2026 results with a 13% revenue increase to $29.6 million and an improved gross margin of 64.2%. Despite a GAAP loss, adjusted net income and EBITDA showed significant gains, driven by operational improvements and strategic initiatives. The company reaffirmed its 2026 guidance and completed a $15 million share repurchase.
Anika Reports First Quarter 2026 Financial Results
Anika Therapeutics Inc. reported strong first-quarter 2026 financial results, with total revenue increasing 13% to $29.6 million and gross margin improving to 64.2%. The company's strategic transformation and operational realignment led to improved profitability, highlighted by a 35% increase in Integrity procedures and double-digit revenue growth in both Commercial and OEM channels. Anika maintains its fiscal 2026 guidance and completed a $15 million share repurchase.
Anika Reports First Quarter 2026 Financial Results
Anika Therapeutics, Inc. reported strong first-quarter 2026 financial results, with a 13% increase in total revenue to $29.6 million and a gross margin improvement to 64.2%. This growth was primarily driven by strength in both its Commercial and OEM Channels, along with operational execution and margin improvement initiatives, leading to an adjusted EBITDA of $4.3 million. The company is maintaining its fiscal 2026 guidance, projecting total revenue between $114 million and $122.5 million.
Anika: Q1 Earnings Snapshot
Anika Therapeutics Inc. (ANIK) reported a first-quarter loss of $5.1 million, or 37 cents per share, though adjusted earnings were 27 cents per share. The medical technology company achieved $29.6 million in revenue and anticipates full-year revenue between $114 million and $122.5 million. Anika's shares have significantly increased, climbing 59% year-to-date and 5% over the past 12 months.
ANIK Financials: Income Statement, Balance Sheet & Cash Flow | Anika Therapeutics Inc
This article provides a detailed financial analysis of Anika Therapeutics Inc (ANIK), covering its income statement, balance sheet, cash flow, and key financial ratios through FY2025 and Q1 2026. The company is characterized by improved free cash flow despite continued net losses, solid liquidity, and a low debt-to-equity ratio. The analysis highlights declining revenue, negative operating margins, and a "mixed" earnings quality, summarized by a neutral Piotroski F-Score and a moderate financial health score of 42/100.
Anika Therapeutics ends Shoulder360 weekend by inviting demo requests for Integrity product
Anika Therapeutics concluded its participation at the Shoulder360 event, where it highlighted its Integrity implant solution. The company is now offering demonstrations of the Integrity product for those who could not attend. This follows a case report showing superior outcomes for Integrity in high-risk rotator cuff patients and a distribution partnership with J&J Medtech for other Anika osteoarthritis therapies.
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
Anika Therapeutics, Inc. announced it will release its first quarter 2026 financial results on Wednesday, April 29, 2026, before market open. The company will host a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the call via phone or a live audio webcast on Anika's investor relations website.
